Recently, a new form of mitochondrial DNA (mtDNA) abnormality, mtDNA depletion, has been reported in several children. Clinically, the syndrome of mtDNA depletion is heterogeneous. Specific tissues (for example, muscle, liver) may be affected in some patients; while in others, mtDNA depletion is a multisystemic disorder. Based on age at onset, two subtypes are distinguished: congenital (or early-onset) and infantile (or later- onset). Although survival is longer in the later-onset form, the syndrome is fatal in almost all patients, and currently there is no effective treatment. In these children, no qualitative defects of mtDNA, such as point mutations or deletions, were found, and depletion of mtDNA is considered the primary etiology. In contrast, mtDNA-depleted muscle fibers have also been found to coexist with fibers harboring deleted mtDNA in diseases such as autosomal dominant progressive external ophthalmoplegia with multiple deletions and inclusion-body myositis. Although the mechanisms leading to mtDNA depletion in these disorders are unknown, this type of depletion is considered secondary. Because of the Mendelian mode of inheritance in patients with primary mtDNA depletion, a defect to nuclear DNA or in intergenomic communication may be responsible for the phenotype. However, no such defect has yet been identified. Currently, the etiology of the etiology of the secondary form of mtDNA depletion is not known. The long-term goals of this project are to identify the pathogenetic mechanisms involved in primary and secondary mtDNA depletion, and to further characterize the roles of secondary mtDNA depletion in diseases caused by qualitative mtDNA defects. A variety of techniques, including in situ hybridization, single-fiber PCR, and tissue cultures, will be employed. The data obtained will enhance our understanding of the pathogenesis of mtDNA depletion and form a basis for the therapeutic strategies. I have available patient material, tissue culture systems, and methodologies necessary for the study mtDNA depletion at the molecular level. I am eager to undertake this study under the sponsorship of Dr. DiMauro and in collaboration with other members of the H. Houston Merritt Clinical Research Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08NS001899-05
Application #
6187481
Study Section
NST-2 Subcommittee (NST)
Program Officer
Nichols, Paul L
Project Start
1996-09-15
Project End
2001-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
5
Fiscal Year
2000
Total Cost
$114,804
Indirect Cost
Name
Columbia University (N.Y.)
Department
Neurology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Vu, Tuan H; Hirano, Michio; DiMauro, Salvatore (2002) Mitochondrial diseases. Neurol Clin 20:809-39, vii-viii
Church, J A; Mitchell, W G; Gonzalez-Gomez, I et al. (2001) Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 138:748-51
Hirano, M; Marti, R; Ferreiro-Barros, C et al. (2001) Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Dev Biol 12:417-27
Vu, T H; Tanji, K; Holve, S A et al. (2001) Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? Hepatology 34:116-20
Vu, T H; Hays, A P; Tanji, K et al. (2001) Myopathy with tubulin-reactive crystalline inclusions. Neurology 57:149-52
Hirano, M; Vu, T H (2000) Defects of intergenomic communication: where do we stand? Brain Pathol 10:451-61
Vu, T H; Tanji, K; Valsamis, H et al. (1998) Mitochondrial DNA depletion in a patient with long survival. Neurology 51:1190-3